Leukopenia early after kidney transplantation: a switch from mycophenolate to mTOR inhibitor appears safe and feasible and improves viral control in a high-risk population
Conflict of interest
The authors declare no conflicts of interest.
Ethical approval
The study was approved by the cantonal ethics commission review board of Zurich, Switzerland (KEK-ZH-Number 2020-02817) and has been conducted in compliance with the Declaration of Helsinki.
Informed consent to participate
All included patients provided written consent to participate.
留言 (0)